Keyphrases
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Antibody Targeting
100%
Ionizing Radiation
100%
Therapeutic Monoclonal Antibody
100%
Tumor Cells
50%
Trastuzumab
50%
Antibody-dependent Cellular Cytotoxicity
50%
Tumor
25%
Response Rate
25%
Breast Cancer Cell Lines
25%
Therapeutic Target
25%
Hematological Malignancies
25%
Monotherapy
25%
Total Protein
25%
Protein Expression
25%
Targeted Therapy
25%
Monoclonal Antibody
25%
Stem Cell Population
25%
Cell Surface
25%
Cytotoxic T Cells
25%
Molecular Targets
25%
Intracellular Reactive Oxygen Species
25%
Surface Proteins
25%
Radiation Exposure
25%
Patient Demographics
25%
Functional Significance
25%
Phenotypic Change
25%
Radiation Effects
25%
Cell Interaction
25%
HER2-targeted Therapy
25%
Cell Toxicity
25%
Solid Malignancies
25%
Immunomodulation
25%
Poor Response
25%
CD20
25%
Antiproliferative Activity
25%
Triple Negative
25%
Medicine and Dentistry
Ionizing Radiation
100%
Monoclonal Antibody Therapy
100%
Antibody Therapy of Cancer
100%
Upregulation
75%
Tumor Cell
50%
Single Drug Dose
50%
Antibody Dependent Cellular Cytotoxicity
50%
Trastuzumab
50%
Neoplasm
25%
Monotherapy
25%
Hematologic Malignancy
25%
Cell Population
25%
Targeted Therapy
25%
Immunotherapy
25%
Cell Surface
25%
Reactive Oxygen Species
25%
Protein Expression
25%
Cytotoxic T-Cell
25%
Radiation Exposure
25%
Monoclonal Antibody
25%
Epidermal Growth Factor Receptor
25%
Patient Population
25%
CD20
25%
Cell Interaction
25%
Sensitization
25%
Breast Cancer Cell Line
25%
Stem Cell
25%
Cell Surface Protein
25%
Antiproliferative Activity
25%
Immunology and Microbiology
Monoclonal Antibody Therapy
100%
Upregulation
75%
Tumor Cell
50%
Cell Surface
50%
Trastuzumab
50%
Antibody-Dependent Cell-Mediated Cytotoxicity
50%
Cell Population
25%
Stem Cell
25%
Monoclonal Antibody
25%
Cytotoxic T Cell
25%
Protein Expression
25%
Immunotherapy
25%
CD20
25%
Cell Interaction
25%
Sensitization
25%
Breast Cancer Cell Line
25%
Antiproliferative Activity
25%